TNF and rheumatoid arthritis: Golimumab is a human IgG1 TNF-α antagonist monoclonal antibody and is approved by the FDA for once-monthly subcutaneous administration as a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.